CALU Gene Mutation Analysis
Calumenin, encoded by the CALU gene, is a molecular chaperone that inhibits transfer of reduced vitamin K from VKORC1, the pharmacological target of warfarin, to the γ-carboxylase. Because of its polymorphic structure and central role in the warfarin metabolic pathway, a contributory role for calumenin to warfarin dose variability has been posited.
There are four known SNPs in the coding region: rs1043550 (3’UTR), rs11653 (3’UTR), rs339097 (intronic), and rs2290228 (11G>A, Arg4Gln). Of these, only rs339097 has been shown to have an effect on warfarin dosage requirements.
- Warfarin therapy selection and optimization
- Predict/optimize warfarin dosage requirements
- rs339097 AA – homozygous wild-type - may require a lower maintenance dose of warfarin compared to patients with GA or GG genotype
- rs339097 AG – heterozygous - may require a higher maintenance dose compared to patients with the AA genotype
- rs339097 GG – homozygous variant – may require a higher dose compared to patients with the AA genotype
Note: Other genetic and clinical factors may also influence warfarin dose.
rs339097 AA – homozygous wild-type - may require a lower maintenance dose of warfarin compared to patients with GA or GG genotype
Buccal swabs or Whole blood.
ACD yellow top tube is preferred, EDTA lavender top tube also accepted.
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Pharmacogenet Genomics. 2011; 21(3):130-5. [PMID: 21228733]
- Clin Pharmacol Ther. 2010 Apr;87(4):445-51. [PMID: 20200517]